ALLURION TECHNOLOGIES INC (ALUR)
OTCHealth CareMedical - DevicesSnapshot 2026-11-04
OTCHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · ALUR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 71.3% |
Growth built into the price is above our model estimate.
The price assumes 156.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
ALUR — officer change
Dated 2026-08-24
Director — Krishna Gupta: Two directors resigned simultaneously, resulting in a reduction of the board size from five to three members.
Why it matters: Management says a national exchange listing could raise the company’s profile and make trading easier. Approval would advance its stated listing goal.
Supportive ifThe company says the NYSE or NYSE American approved its listing. Its shares then start trading there.
Worry ifThe company says it did not meet exchange listing rules, or that the exchange rejected its relisting plan.
Why it matters: Two directors left at once, cutting the board from five members to three. A new plan would show how the smaller board will guide oversight.
Watch forThe company names new directors or reports a board plan that brings the board to at least five members.
Also watch forMore directors leave the company, or the board stays at three members without naming replacements.
Why it matters: The FDA-approved balloon is a stated growth priority, but revenue fell to $2.95M in 2026-Q1. Higher sales would show stronger commercial traction.
Supportive ifA reported quarter shows revenue above $2.95M, with the company linking growth to U.S. sales of the FDA-approved balloon.
Worry ifA reported quarter shows revenue at or below $2.95M, with no stated growth in U.S. balloon sales.
Why it matters: The operating loss has improved, reaching $3.7M in 2026-Q1. Further cuts would support management's cost goal; a wider loss would break that trend.
Watch forA reported quarter shows an operating loss below $3.7M.
Also watch forA reported quarter shows an operating loss above $3.7M.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$580 on $10,000 · ±5.8% | How much price usually moves either way. |
| Bad day | $2,186 loss on $10,000 · 21.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,954 loss on $10,000 · 99.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.